ENIGMATIG LTD EGG
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS0.02
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $4.5M | $4.0M | $4.6M | — |
| Cost of revenue | $1.4M | $1.3M | $1.5M | — |
| Gross profit | $3.1M | $2.7M | $3.1M | — |
| Total operating expenses | $2.5M | $1.6M | $1.7M | — |
| Operating income | $538.0K | $1.0M | $1.5M | — |
| Pre-tax income | $855.2K | $963.4K | $1.4M | — |
| Income tax | $295.5K | $142.2K | $242.6K | — |
| Net income | $559.7K | $821.2K | $1.1M | — |
| EPS, basic | 0.02 | 0.03 | 0.05 | — |
| EPS, diluted | 0.02 | 0.03 | 0.05 | — |
| Shares, diluted (wtd. avg.) | $25.9M | $25.0M | $25.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $13.2M | $1.6M | $1.2M | $447.9K |
| Receivables | $1.2M | $1.1M | — | — |
| Total current assets | $15.1M | $3.4M | — | — |
| Property, plant and equipment | $218.4K | $731 | — | — |
| Total assets | $18.2M | $3.5M | $4.0M | — |
| Accounts payable | $334.9K | $328.0K | — | — |
| Total current liabilities | $1.8M | $1.7M | — | — |
| Total liabilities | $2.2M | $1.7M | — | — |
| Retained earnings | $2.1M | $1.5M | — | — |
| Total equity | $16.0M | $1.8M | $812.7K | -$344.8K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$1.7M | -$602.9K | -$58.7K | — |
| Depreciation and amortisation | $33.0K | $5.8K | $1.7K | — |
| Capital expenditure | $246.1K | $3.2K | $4.1K | — |
| Investing cash flow | -$275.8K | $1.9M | $451.5K | — |
| Financing cash flow | $13.7M | -$1.1M | $347.3K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-006963.
Others in SIC 8742
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| BAH | Booz Allen Hamilton Holding Corp | $8.76B | 10.6x | -6.4% |
| G | Genpact LTD | $6.27B | 11.9x | 6.6% |
| FCN | FTI CONSULTING, INC | $4.19B | 18.4x | 2.4% |
| EXPO | EXPONENT INC | $3.25B | 33.0x | 4.2% |
| HURN | Huron Consulting Group Inc. | $2.52B | 26.6x | 11.9% |
| ASTH | Astrana Health, Inc. | $2.14B | 83.6x | 56.4% |
| ICFI | ICF International, Inc. | $1.58B | 17.8x | -7.3% |
| BWMN | Bowman Consulting Group Ltd. | $735.5M | 58.1x | 14.9% |